| Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label … PG Richardson, A Oriol, M Beksac, AM Liberati, M Galli, F Schjesvold, ... The Lancet Oncology 20 (6), 781-794, 2019 | 369 | 2019 |
| Reduced-intensity transplantation for lymphomas using haploidentical related donors vs HLA-matched unrelated donors AS Kanate, A Mussetti, MA Kharfan-Dabaja, KW Ahn, A DiGilio, ... Blood, The Journal of the American Society of Hematology 127 (7), 938-947, 2016 | 296 | 2016 |
| PD-1 blockade for relapsed lymphoma post–allogeneic hematopoietic cell transplant: high response rate but frequent GVHD BM Haverkos, D Abbott, M Hamadani, P Armand, ME Flowers, ... Blood, The Journal of the American Society of Hematology 130 (2), 221-228, 2017 | 281 | 2017 |
| Indications for hematopoietic cell transplantation and immune effector cell therapy: guidelines from the American Society for Transplantation and Cellular Therapy AS Kanate, NS Majhail, BN Savani, C Bredeson, RE Champlin, ... Biology of Blood and Marrow Transplantation 26 (7), 1247-1256, 2020 | 214 | 2020 |
| Standardizing definitions of hematopoietic recovery, graft rejection, graft failure, poor graft function, and donor chimerism in allogeneic hematopoietic cell transplantation … MA Kharfan-Dabaja, A Kumar, E Ayala, M Aljurf, T Nishihori, R Marsh, ... Transplantation and cellular therapy 27 (8), 642-649, 2021 | 97 | 2021 |
| R‐CHOP versus dose‐adjusted R‐EPOCH in frontline management of primary mediastinal B‐cell lymphoma: a multi‐centre analysis NN Shah, A Szabo, SF Huntington, N Epperla, N Reddy, S Ganguly, ... British journal of haematology 180 (4), 534-544, 2018 | 96 | 2018 |
| Summary of scientific and statistical methods, study endpoints and definitions for observational and registry-based studies in hematopoietic cell transplantation AS Kanate, A Nagler, B Savani Clinical Hematology International 2 (1), 2-4, 2020 | 78 | 2020 |
| Allogeneic haematopoietic cell transplantation for extranodal natural killer/T-cell lymphoma, nasal type: a CIBMTR analysis AS Kanate, A DiGilio, KW Ahn, M Al Malki, E Jacobsen, A Steinberg, ... British journal of haematology 182 (6), 916, 2018 | 76 | 2018 |
| Autologous transplantation versus allogeneic transplantation in patients with follicular lymphoma experiencing early treatment failure SM Smith, J Godfrey, KW Ahn, A DiGilio, S Ahmed, V Agrawal, ... Cancer 124 (12), 2541-2551, 2018 | 76 | 2018 |
| Predictive factors and outcomes for ibrutinib therapy in relapsed/refractory mantle cell lymphoma—a “real world” study N Epperla, M Hamadani, AF Cashen, KW Ahn, E Oak, AS Kanate, ... Hematological oncology 35 (4), 528-535, 2017 | 72 | 2017 |
| Superior serum concentrations with posaconazole delayed-release tablets compared to suspension formulation in hematological malignancies A Cumpston, R Caddell, A Shillingburg, X Lu, S Wen, M Hamadani, ... Antimicrobial agents and chemotherapy 59 (8), 4424-4428, 2015 | 67 | 2015 |
| Plasmablastic lymphoma versus plasmablastic myeloma: an ongoing diagnostic dilemma JS Ahn, R Okal, JA Vos, M Smolkin, AS Kanate, FG Rosado Journal of Clinical Pathology 70 (9), 775-780, 2017 | 66 | 2017 |
| A prognostic model predicting autologous transplantation outcomes in children, adolescents and young adults with Hodgkin lymphoma P Satwani, KW Ahn, J Carreras, H Abdel-Azim, MS Cairo, A Cashen, ... Bone marrow transplantation 50 (11), 1416-1423, 2015 | 65 | 2015 |
| Maintenance therapies for Hodgkin and non-Hodgkin lymphomas after autologous transplantation: a consensus project of ASBMT, CIBMTR, and the Lymphoma Working Party of EBMT AS Kanate, A Kumar, P Dreger, M Dreyling, S Le Gouill, P Corradini, ... JAMA oncology 5 (5), 715-722, 2019 | 60 | 2019 |
| Lower graft-versus-host disease and relapse risk in post-transplant cyclophosphamide–based haploidentical versus matched sibling donor reduced-intensity conditioning transplant … S Ahmed, JA Kanakry, KW Ahn, C Litovich, H Abdel-Azim, M Aljurf, ... Biology of blood and marrow transplantation 25 (9), 1859-1868, 2019 | 59 | 2019 |
| Allogeneic hematopoietic cell transplant for acute myeloid leukemia: Current state in 2013 and future directions AS Kanate, MC Pasquini, PN Hari, M Hamadani World journal of stem cells 6 (2), 69, 2014 | 50 | 2014 |
| Myeloablative vs reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chronic myeloid leukemia S Chhabra, KW Ahn, ZH Hu, S Jain, A Assal, J Cerny, EA Copelan, A Daly, ... Blood advances 2 (21), 2922-2936, 2018 | 47 | 2018 |
| Impact of pretransplantation 18f-fluorodeoxy glucose–positron emission tomography status on outcomes after allogeneic hematopoietic cell transplantation for non-Hodgkin lymphoma V Bachanova, LJ Burns, KW Ahn, GG Laport, G Akpek, ... Biology of Blood and Marrow Transplantation 21 (9), 1605-1611, 2015 | 42 | 2015 |
| Post-transplant cyclophosphamide versus anti-thymocyte globulin for graft-versus-host disease prevention in haploidentical transplantation for adult acute lymphoblastic leukemia A Nagler, AS Kanate, M Labopin, F Ciceri, E Angelucci, Y Koc, Z Gülbas, ... haematologica 106 (6), 1591, 2021 | 41 | 2021 |
| Priorities and uncertainties of administering chemotherapy in a pregnant woman with newly diagnosed colorectal cancer AS Kanate, ML Auber, GM Higa Journal of Oncology Pharmacy Practice 15 (1), 5-8, 2009 | 39 | 2009 |
